Gangliosides and the Guillain-Barre syndrome No causal link

Samson, Jaap C.; Fiori, Marina

doi:10.1136/bmj.308.6929.653a

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, Yuki et al () reported the development of motor neuron disease‐like disorders after GM1 therapy in a 71‐year‐old patient. In this regard, after careful review of available data, no definite relationship between ganglioside administration and GBS and peripheral neuropathies could be established (Grigoletto, ; Samson and Fiori, ; Govoni et al, ). Why does ganglioside treatment in humans have different outcomes depending on the study?…”

Section: Strategies For the Treatment Of Neurodegenerative Diseasesmentioning

confidence: 99%

Pathogenic role of ganglioside metabolism in neurodegenerative diseases

Ariga

2014

J of Neuroscience Research

View full text Add to dashboard Cite

Ganglioside metabolism is altered in several neurodegenerative diseases, and this may participate in several events related to the pathogenesis of these diseases. Most changes occur in specific areas of the brain and their distinct membrane microdomains or lipid rafts. Antiganglioside antibodies may be involved in dysfunction of the blood-brain barrier and disease progression in these diseases. In lipid rafts, interactions of glycosphingolipids, including ganglioside, with proteins may be responsible for the misfolding events that cause the fibril and/or aggregate processing of disease-specific proteins, such as α-synuclein, in Parkinson's disease, huntingtin protein in Huntington's disease, and copper-zinc superoxide dismutase in amyotrophic lateral sclerosis. Targeting ganglioside metabolism may represent an underexploited opportunity to design novel therapeutic strategies for neurodegeneration in these diseases.

show abstract

Section: Strategies For the Treatment Of Neurodegenerative Diseasesmentioning

confidence: 99%

Pathogenic role of ganglioside metabolism in neurodegenerative diseases

Ariga

2014

J of Neuroscience Research

View full text Add to dashboard Cite

show abstract

“…J C Sampson and M G Fiori misleadingly state that our 5.6 cases per year “represent a yearly incidence of 0.2/100 000”3 - but this is a three week incidence, the yearly incidence being 3.5/100 000. They further argue against comparing the incidence of Guillain-Barre syndrome in the normal population with that in patients treated with gangliosides, “that is, patients with neuropathy.” However, only two of our cases had received gangliosides - for eight and for 10 days - for “neuropathy,” unilateral Bell's palsy, a highly improbable presentation of the syndrome with this time course.…”

mentioning

confidence: 91%